TGF‐β seems to be a key player in the reprogramming of the tumour microenvironment (TME), and peer‐reviewed data demonstrate that TGF‐β inhibitors may restore immune responses to cancer [24]. The gene discussed is TGFB1; the disease is neoplasm.